Afya (NasdaqGS:AFYA) is back in focus after recent share performance, with the stock flat over the past day but up over the past week and month, prompting closer attention to its valuation and fundamentals.

Over the past month Afya has shown improving momentum, with a 1 month share price return of 6.14% contrasting with a year to date share price return that is slightly down and a 1 year total shareholder return that has also declined.

If you are comparing Afya with other opportunities in the market, this is a useful moment to broaden your search and check out 20 top founder-led companies

So with Afya shares recovering over the past month but still showing weaker returns over the past year and longer, is the stock quietly undervalued today, or is the market already pricing in any future growth?

Most Popular Narrative: 13.8% Undervalued

Afya's most followed narrative points to a fair value of $17.25 per share, compared with the last close at $14.87. This puts the focus firmly on whether the current price reflects its long term earnings potential.

Digital initiatives and cross segment integration including Medical Practice Solutions and Continuing Education are increasing recurring, higher margin digital revenues and operational synergies, which should lead to sustained net margin expansion and greater earnings stability.

Read the complete narrative. Read the complete narrative.

Want to understand why this narrative points to a higher fair value for Afya? It hinges on a specific path for revenue growth, shifting margins and how much investors might pay for those future earnings. The key assumptions sit behind a detailed earnings trajectory and a tighter share count that could meaningfully change per share outcomes.

Result: Fair Value of $17.25 (UNDERVALUED)

However, Afya’s story could look different if rising competition for medical students pressures tuition or if higher and less predictable tax rates weigh on earnings.

Next Steps

With mixed sentiment around Afya's recent performance and valuation, this is a good time to look through the key data points yourself and weigh both sides. To see how investors are assessing the balance between potential rewards and risks, review the 4 key rewards and 1 important warning sign

Looking for more investment ideas beyond Afya?

If Afya has caught your attention, do not stop there. Broaden your watchlist now so you are not the one spotting opportunities after everyone else.

• Target resilient cash generators by checking companies in the solid balance sheet and fundamentals stocks screener (48 results) that pair financial strength with solid fundamentals.
• Hunt for potential value opportunities using the 42 high quality undervalued stocks to see stocks that combine quality metrics with pricing that may look appealing.
• Protect your downside by reviewing the 70 resilient stocks with low risk scores and focus on stocks with lower overall risk profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.